echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first domestic "Regulations for the Management of Autologous CAR-T Cell Drug Supply Chains" will be implemented on October 18

    The first domestic "Regulations for the Management of Autologous CAR-T Cell Drug Supply Chains" will be implemented on October 18

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 13, 2021, the National Group Information Platform released the group standard of "Autologous CAR-T Cell Drug Supply Chain Management Regulations" (T/SHPPA 011—2021) drafted by Shanghai Pharmaceutical Industry Association and Shanghai Drug Evaluation and Verification Center.
    , The standard will be implemented on October 18, 2021
    .


    This "Regulations for the Management of Autologous CAR-T Cell Drug Supply Chain" group standards stipulates the management requirements of the autologous CAR-T cell drug supply chain, including the responsibilities of MAH and related parties in the autologous CAR-T cell drug supply chain, digital information platforms, and facilities Equipment, logistics operations, transportation of donor materials and autologous CAR-T cell medicines, storage of autologous CAR-T cell medicines, delivery of autologous CAR-T cell medicines, handling of abnormal situations, recalls, disposal of non-conforming products, document records, etc.


    1.
    How much do you know about autologous CAR-T cell drugs?

    1.
    How much do you know about autologous CAR-T cell drugs?

    CAT-T cells, or chimeric antigen receptor T cells, use genetic modification technology to transfer genetic material with specific antigen recognition domains and T cell activation signals into T cells, allowing T cells to directly interact with tumor cells on the surface It is activated by combining with specific antigens, and directly kills tumor cells by releasing perforin, granzyme B, etc.
    , and at the same time recruiting human endogenous immune cells to kill tumor cells by releasing cytokines, so as to achieve T cells for the purpose of treating tumors
    .


    Gene therapy products used to be just a theory.


    2.


    2.


    3.


    3.


    4.


    4.


    references

    [1] Shanghai Pharmaceutical

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.